Invst Guru
Posts
Revolutionizing Respiratory Care: The Health Care Originals Vision

Revolutionizing Respiratory Care: The Health Care Originals Vision

How AI and Wearable Technology are Transforming Asthma and COPD Management for a Healthier Tomorrow

December 15, 2024

In partnership with

Crowdfunding Has Never Been This Easy

Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Wednesday and Sunday, we connect startups with the power of the crowd and provide investors with access to groundbreaking ventures.

In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.

🔦 Invest in the Future of Respiratory Care: Health Care Originals

Imagine a world where asthma attacks and COPD flare-ups can be predicted and mitigated in real-time, where patients can sleep soundly without the fear of sudden respiratory distress, and where healthcare providers can intervene before emergencies occur. Health Care Originals (HCO) is making this vision a reality.

With over 1,000 patients treated and 12,000 more waiting to access its revolutionary technology, HCO stands at the forefront of transforming respiratory care. This equity crowdfunding campaign on Wefunder offers a unique opportunity to join the future of healthcare by investing in a company that is solving one of the most pressing challenges in global health.

The Problem: An $83 Billion Market in Need of Innovation Asthma and Chronic Obstructive Pulmonary Disease (COPD) affect millions globally, accounting for a significant share of the $83 billion respiratory care market. Despite the prevalence of these diseases, current solutions are often reactive rather than proactive, leading to avoidable hospitalizations, increased healthcare costs, and diminished quality of life for patients.

HCO’s mission is clear: to redefine how we manage respiratory conditions by shifting from reactive care to predictive, preventative, and personalized solutions.

The Solution: Cutting-Edge AI and Wearable Technology HCO’s proprietary platform combines advanced AI algorithms with wearable technology to deliver real-time insights into patients’ respiratory health. This innovation empowers users to take control of their conditions, significantly reducing the risk of severe episodes and enhancing their overall quality of life.

Clinical Impact: In just six months, 67% of users report zero asthma attacks or COPD flare-ups, while 90% experience improved sleep quality. These outcomes are life-changing for patients and a game-changer for healthcare providers.
Ease of Adoption: The platform integrates seamlessly into existing healthcare systems. Its progress on the FDA 510(k) clearance pathway and coverage under current reimbursement codes ensures that adoption is practical and scalable.

Why Now? The Market Opportunity Respiratory care is an underserved market with immense growth potential. HCO’s technology addresses a critical need for solutions that improve patient outcomes while reducing healthcare costs. The company is well-positioned for exponential growth with contracts already in place projecting $5.5 million in annual recurring revenue and a forecast of $35 million by 2026. It is important to note that while these projections are impressive, they are not guaranteed.

Innovation Backed by Intellectual Property HCO has developed a robust portfolio with 13 allowed patents and 10 pending. This strong IP foundation protects the company’s technology and positions it as a leader in the respiratory care industry.

A Leadership Team Poised for Success HCO’s leadership includes seasoned executives with decades of experience in healthcare and medtech. With expertise from companies like Lark Health and Blue Cross, the team brings the strategic vision and operational excellence needed to drive the company forward.

A Community-Focused Investment Opportunity Through its equity crowdfunding campaign on Wefunder, HCO invites investors to join its journey. Here are the details:

Valuation: $13 million pre-money valuation.
Share Price: $1.5175 per share.
Early Bird Bonus: Investors who act quickly will receive 1.5 times the number of shares purchased in warrants, enhancing the value of their investment.

This is your chance to align with a mission-driven company that combines cutting-edge technology, a proven market need, and a strong leadership team to address a critical healthcare challenge.

Recent Milestones and Recognition HCO’s innovative approach has not gone unnoticed:

Board Appointment: Timothy Bowe, a medtech veteran with over 40 years of experience, has joined HCO’s Board of Directors to guide its growth strategy.
Industry Accolades: Recognized as a SuperCrowd Top Impact Innovator and spotlighted by Chloe Capital for its contributions to digital health, HCO is earning accolades for its transformative impact.

Why Invest? HCO’s campaign offers more than financial returns; it’s an opportunity to support a company making a tangible difference in people’s lives. By investing, you’re not just funding a business—you’re helping to reshape the future of respiratory care.

Join the Movement Every investment in HCO is a step toward a healthier, more resilient world. Don’t miss your chance to be part of this groundbreaking venture. Visit their Wefunder page today to learn more and secure your stake in the future of healthcare.